Načítá se...
Targeting a neoantigen derived from a common TP53 mutation
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at positi...
Uloženo v:
| Vydáno v: | Science |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8208645/ https://ncbi.nlm.nih.gov/pubmed/33649166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.abc8697 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|